奥卡西平与左乙拉西坦治疗新诊癫痫的疗效

目的:观察奥卡西平与左乙拉西坦治疗新诊癫痫的疗效及对血脂、骨代谢的影响。方法:107例新诊的原发性癫痫患者随机分为奥卡西平组(52例)和左乙拉西坦组(55例),分别给予奥卡西平或左乙拉西坦单药治疗。治疗6月后观察2组疗效以及血脂指标、骨代谢指标变化情况。结果:2组疗效比较差异均无统计学意义(P0.05);治疗后,2组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)均较治疗前升高(P0.05),高密度脂蛋白胆固醇(HDL-C)较治疗前无明显变化(P0.05),2组之间TC、TG、LDL-C、HDL-C水平比较差异无统计学意义(P0.05);治疗后,2组碱性磷酸酶(ALP)、骨特异性碱性磷酸酶(BAP)、磷(P)、钙(Ca)、甲状旁腺素(PTH)水平与治疗前比较差异无统计学意义(P0.05),2组之间比较差异无统计学意义(P0.05)。结论:奥卡西平与左乙拉西坦治疗癫痫疗效相当,应用半年即有导致血脂升高,但短期应用对骨代谢影响不明显。

Therapeutic Effect of Oxcarbazepine and Levetiracetam in Patients with Newly Diagnosed Epilepsy

Objective:To observe the efficacy and influence on blood lipids, bone metabolism of oxcarbazepine and levetiracetam in treatment of newly diagnosed primary epilepsy. Methods: One hundred and seven patients with newly diagnosed primary epilepsy were randomly divided into oxcarbazepine group (52 cases) and levetirac-etam group (55 cases). The oxcarbazepine group was given Oxcarbazepine, and the levetiracetam group was given levetiracetam. After 6 months of the treatment, the efficacy and level of blood lipids, bone mineral density of the two groups were observed. Results: The efficacy in the two groups showed no significant difference (P>0.05). TC, TG and LDL-C levels were increased significantly after the treatment in both the groups. There was no significant difference of HDL-C level before and after treatment. The levels of TC, TG, LDL-C and HDL-C in the two groups showed no statistical differences (P>0.05). The ALP, BAP, P, CA and PTH levels showed no significant differences before and after the treatment in both groups (P>0.05), and there was no statistical differences of these levels be-tween the two groups(P>0.05). Conclusion: Oxcarbazepine and Levetiracetam have similar therapeutic efficacy in treating epilepsy. Both of them increase blood lipids after six-month treatment, however, influences on bone metabolism is not obvious at the same time point.